Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 May 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

11 May 2022 Status changed from recruiting to completed.
01 Aug 2021 Primary endpoint has been met. (Number of patients responding to treatment) as per Results published in the Hematological Oncology
01 Aug 2021 Results analysing efficacy of idelalisib and rituximab (IR) in patients with relapsed/refractory chronic lymphocytic leukemia treated at GIMEMA centers published in the Hematological Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com